Ubenimex
From Wikipedia, the free encyclopedia
Ubenimex[1] | ||
---|---|---|
IUPAC name (2S)-2-[[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid | ||
Other names Bestatin; N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine | ||
Identifiers | ||
CAS number | 58970-76-6, 65391-42-6 (HCl) | |
PubChem | 72172 | |
ChEMBL | CHEMBL29292 | |
Jmol-3D images | {{#if:CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O|Image 1 | |
| ||
Properties | ||
Molecular formula | C16H24N2O4 | |
Molar mass | 308.37 g mol−1 | |
Melting point | 245 °C (dec.) | |
Hazards | ||
S-phrases | S22 S24/25 | |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | ||
Infobox references | ||
Ubenimex (INN), also known as bestatin, is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B,[2] leukotriene A4 hydrolase,[3] aminopeptidase N.[4] It is being studied for use in the treatment of acute myelocytic leukemia.[5]
References
- ↑ N-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl)-L-leucine at Sigma-Aldrich
- ↑ Umezawa,H., Aoyagi,T., Suda,H., Hamada,M. & Takeuchi,T. (1976). Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. (29). pp. 97–99.
- ↑ Muskardin,D.T., Voelkel,N.F. & Fitzpatrick,F.A. (1994). Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase. (48). pp. 131–137.
- ↑ K Sekine, H Fujii and F Abe (1999). Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines 13 (5). pp. 729–734.
- ↑ Hirayama, Y; Sakamaki, S; Takayanagi, N; Tsuji, Y; Sagawa, T; Chiba, H; Matsunaga, T; Niitsu, Y (2003). "Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival". Gan to kagaku ryoho. Cancer & chemotherapy 30 (8): 1113–8. PMID 12938265.
External links
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.